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Abstract
Introduction: Interleukin (IL)-27 is a novel member of the IL-6/IL-12 family cytokines that are produced early by 
antigen-presenting cells in T helper (Th)1-mediated inflammation. Elevated expression of IL-27 has been detected in 
the synovial membranes and fluid of rheumatoid arthritis (RA).
Methods: We investigated the in vitro effects of IL-27, alone or in combination with inflammatory cytokine tumor 
necrosis factor (TNF)-α or IL-1 β on the pro-inflammatory activation of human primary fibroblast-like synoviocytes (FLS) 
from RA patients and normal control subjects, and the underlying intracellular signaling molecules were determined 
by intracellular staining using flow cytometry.
Results: Significantly higher plasma concentration of IL-27 was found in RA patients (n = 112) than control subjects (n 
= 46). Both control and RA-FLS constitutively express functional IL-27 receptor heterodimer, gp130 and WSX-1, with 
more potent IL-27-mediated activation of signal transducers and activators of transcription (STAT)1 in RA-FLS. IL-27 was 
found to induce significantly higher cell surface expression of intercellular adhesion molecule (ICAM)-1 and vascular 
cell adhesion molecule (VCAM)-1 and release of inflammatory chemokine IL-6, CCL2, CXCL9, CXCL10 and matrix 
metalloproteinase-1 of RA-FLS than that of control FLS (all P < 0.05). Moreover, an additive or synergistic effect was 
observed in the combined treatment of IL-27 and TNF-α or IL-1 β on the surface expression of ICAM-1 and VCAM-1 and 
the release of CXCL9 and CXCL10 of RA-FLS. Further investigations showed that the expression of ICAM-1, VCAM-1 and 
chemokines stimulated by IL-27 was differentially regulated by intracellular activation of phosphatidylinositol 3-OH 
kinase-AKT, c-Jun amino-terminal kinase and Janus kinase pathways.
Conclusions: Our results therefore provide a new insight into the IL-27-activated immunopathological mechanisms 
mediated by distinct intracellular signal transductions in joint inflammation of RA.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease with 1% prevalence in the industrialized countries,
characterized by cytokine-mediated inflammation of the
synovial lining of the diarthrodial joints and the destruc-
tion of cartilage and bone [1]. Together with T and B lym-
phocytes and macrophages, fibroblast-like synoviocytes
(FLS) play crucial roles in both joint damage and the
propagation of inflammation in RA [2]. Normal synovial
tissue consists of two anatomically distinct layers: a sur-
face layer (intima or synovial lining) and an underlying
layer (subintima). The predominant cell types in the nor-
mal intima and subintima are macrophage-like (type A)
synoviocytes and FLS (type B synoviocytes). FLS are
bipolar, spindle-shaped cells with prominent secretory
machinery, including extensive endoplasmic reticulum,
regular ribosomal arrays and well-developed Golgi appa-
ratus [2]. FLS can mediate cartilage and bone destruction
in RA mainly via the elucidation of matrix metalloprotei-
nases (MMPs) such as MMP-1 [3]. Additionally, FLS can
secrete receptor activators of nuclear factor-κB ligand
(RANKL) that attract macrophages from the vasculature;
stimulate the differentiation of vascular- and tissue-
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derived macrophages into osteoclasts; and activate osteo-
clasts at the bone surface, leading to bone erosion [4].
FLS mediates inflammation and autoimmunity through
a wide range and complex mechanisms during the devel-
opment of RA [2]. In RA, FLS respond to inflammatory
cytokines including interleukin (IL)-1β, 6, 8, 12, 17, 18,
21, tumor necrosis factor (TNF)-α and interferon (IFN)-γ
through the activation of multiple intracellular signaling
pathways including extracellular signal-regulated protein
kinase (ERK), c-Jun amino-terminal kinase (JNK) and
p38 mitogen activated protein kinase (MAPK), leading to
the expression of multiple cytokines such as IL-1β, IL-6,
and TNF-α, as well as the secretion of MMPs that con-
tribute to tissue destruction [3,5-8]. Adhesion molecules
present on the FLS surface, including CD44, vascular cell
adhesion molecule (VCAM), and intercellular adhesion
molecule (ICAM), regulate the trafficking of leukocytes
into and/or through the synovial tissue [9]. Direct contact
between FLS and T cells can induce T cell activation [10].
Secretion of IL-15 from FLS, along with the other cytok-
ines, activates T cells, neutrophils and macrophages [10].
IL-27 is a heterodimeric cytokine composed of EBV-
induced protein 3 (EBI3) and p28 subunit that signals
through a receptor complex composed of the unique IL-
27Rα (IL-27R) (WSX-1/T cell cytokine receptor (TCCR))
and gp130 signaling subunit. IL-27 belongs to IL-6/IL-12
family of structurally related ligands that include IL-12,
IL-23 and IL-6 [11,12]. IL-27 receptor has been found to
be expressed on naïve T cells, NK cells, monocytes, mast
cells, activated B cells, Langerhan's cells and activated
dendritic cells, whereas IL-27 is produced mainly by acti-
vated macrophages and dendritic cells [11,12]. IL-27 can
induce a T helper (Th) type 1 response and the expres-
sion of T-bet and interferon (IFN)-γ by naïve T cells
[11,13]. In innate immunity, IL-27 can provoke the pro-
duction of IL-1β, TNF-α, IL-18 and IL-12 in monocytes
[14]. However, more recent studies revealed that IL-27
can play a regulatory role by suppressing the acquired
immunity, inducing the development of Th cells, and
expansion of inducible regulatory T cells to produce IL-
10 [11,15-17]. However, the molecular basis for pleiotro-
pic actions of IL-27 in various immune responses has not
been well elucidated yet. In animal studies of RA, admin-
istration of IL-27 can attenuate collagen-induced arthritis
at the disease onset stage in mice [17]. However, in clini-
cal studies, elevated protein and gene expression IL-27
has been detected in the established RA synovial mem-
branes and fluid [17]. Moreover, IL-27 can induce a Th1
immune response and susceptibility to proteoglycan-
induced arthritis in murine model [18]. Consistent with
these findings, adjuvant-induced arthritis in rats and
experimental autoimmune encephalomyelitis in mice can
be abolished by anti-IL-27 antibodies [19]. Therefore, the
immunopathological roles of IL-27 on the activation of
F L S  i n  R A  r e m a i n e d  u n s e t t l e d ,  p a r t i c u l a r  a t  t h e  l o c a l
inflammatory joints. In an attempt to further elucidate
the immunopathological roles of IL-27 in the joint
inflammation of RA, the in vitro activating effect of IL-27
in combination with TNF-α or IL-1β on FLS from RA and
control subjects and its underlying intracellular signal
mechanism was investigated in this study.
Materials and methods
RA patients, control subjects and blood samples
Patients with active RA (n = 112), who fulfilled the Amer-
ican College of Rheumatology 1987 criteria for RA [20],
were enrolled in this study. Patients eligible for the study
included those with active RA despite treatment with at
least 12.5 mg of methotrexate per week. Active RA was
defined by the presence of at least four swollen and ten-
der joints and in addition at least two of the following:
morning stiffness lasting at least 45 minutes, erythrocyte
sedimentation rate (ESR) Westegren of at least 28 mm/h,
and a serum C-reactive protein concentration of at least
20 mg/L [21]. Forty-six sex- and age-matched healthy
Chinese volunteers were recruited as control subjects. Six
m L  o f  E D T A  v e n o u s  p e r i p h e r a l  b l o o d  w e r e  c o l l e c t e d
from each patient and control subject. The above proto-
col was approved by the Clinical Research Ethics Com-
mittee of The Chinese University of Hong Kong-New
Territories East Cluster Hospitals, and informed consent
was obtained from all participants according to the Dec-
laration of Helsinki.
Reagents
Recombinant human IL-27 and TNF-α were purchased
from R & D Systems, Minneapolis, MN, USA. ERK inhib-
itor PD98059, JNK inhibitor SP600125, p38 MAPK inhib-
itor SB203580, phosphatidylinositol 3-OH kinase (PI3K)
inhibitor LY294002 and Janus kinase (JAK) inhibitor
AG490 were purchased from Calbiochem Corp, San
Diego, CA, USA. SB203580 was dissolved in water while
PD98059, LY294002, SP600125 and AG490 were dis-
solved in dimethyl sulfoxide (DMSO). In all studies, the
concentration of DMSO was 0.1% (vol/vol).
Endotoxin-free solutions
Cell culture medium was purchased from Cell Applica-
tions Inc., San Diego, CA, USA, free of detectable
lipopolysaccharide (< 0.1 EU/ml). All other solutions
were prepared using pyrogen-free water and sterile poly-
propylene plastic ware. No solution contained detectable
L P S ,  a s  d e t e r m i n e d  b y  t h e  L i m u l u s  a m o e b o c y t e  l y a s e
assay (sensitivity limit 12 pg/ml; Biowhittaker Inc, Walk-
ersville, MD, USA).
Cell culture of FLS
Human FLS isolated from synovial tissues obtained from
normal healthy subjects and patients with RA were pur-Wong et al. Arthritis Research & Therapy 2010, 12:R129
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chased from Cell Applications. FLS was cultured in syn-
oviocyte growth medium including 10% synoviocyte
growth supplement (Cell Applications) in 5% CO2 - 95%
humidified air at 37 C [22].
Quantitative PCR of GP-130 and WSX-1 gene expression
Total RNA of FLS was extracted using RNeasy Mini Kit
(Qiagen Inc., Valencia, CA, USA). All RNA samples were
pre-treated with deoxyribonuclease I (Invitrogen Corp.,
Grand Island, CA, USA) and then stored at -70°C. For
each treatment, approximately 1 μ g of total RNA was
reversely transcribed to complementary DNA (cDNA)
with TaqMan Reverse Transcription Reagents (Applied
Biosystems Inc., Foster City, CA, USA). The mRNA
expression of GP-130, WSX-1 and GAPDH (endogenous
control) was quantified by real-time PCR using SYBR
Green probe (Roche Diagnostics Corp., Indianapolis, IN,
USA) with the use of Applied Biosystems 48-well Ste-
pOne™ Real Time PCR System. The primers human GP-
130, WSX-1 and GAPDH were as follows, human hgp130
forward: 5'-TCTGGGAGTGCTGTTCTGCTT-3', human
gp130 reverse: 5'-TGTGCCTTGGAGGAGTGTGA-3';
human wsx-1 forward: 5'-GCTCCTGCCTCTATGTT-
GGC-3', human wsx-1 reverse: 5'-CCTTCATGTTCTT-
GGACCAGC-3'; GAPDH forward: 5'-ATGGGGA
AGGTGAAGGTCG-3', GAPDH reverse: 5'-GGGGT-
CATTGATGGCAACAATA-3'. Real-time PCR was per-
formed in a 25 L reaction mixture containing primers,
FastStart Universal SYBR Green master (ROX) reagent
(Roche) and cDNA sample in duplicate. A negative PCR
control without template and a positive PCR control
(GAPDH) with a template of known amplification cycle
were included. The real-time PCR reaction was per-
formed with 95°C for 15 sec to denature cDNA, 60°C for
60 sec to allow the SYBR green probe and primers to
anneal to the denatured cDNA. The cycles were repeated
40 times after an initial 10-minute denaturation at 95°C.
The threshold cycle (Ct) is the PCR cycle at which an
increase in reporter signal above the baseline signal can
first be detected. The relative GP-130 and WSX-1 mRNA
expression (n = 3) was obtained by comparing with the
relative expression of GAPDH using 2-ΔCt (Ct,gp130/wsx-1 -
Ct,GAPDH).
Western blot analysis
Cells were washed, lysed, and an equal amount of pro-
teins to ensure equal protein loading was subjected to
SDS-PAGE and then blotted onto PVDF membrane (GE
Healthcare Corp, Piscataway, NJ, USA). The membrane
was blocked with 5% skimmed milk and probed with pri-
mary antibody against WSX-1 at 4°C overnight. After
washing, the membrane was incubated with secondary
antibody coupled to horseradish peroxidase (GE Health-
care) for one hour at room temperature. Antibody-anti-
gen complexes were then detected using an ECL
chemiluminescent detection system (GE Healthcare).
Assay of human cytokines, chemokines and MMP-1
Plasma concentration of IL-27 was quantitated by ELISA
reagent from R & D Systems. The concentration of
chemokine CXCL9, CXCL10, CCL2 and CCL5 in culture
supernatant with equal cell number loading was mea-
sured simultaneously by bead-based multiplex cytokine
assay with BD cytometric bead array (CBA) (BD Biosci-
ences Pharmingen, San Diego, CA, USA) using a four-
color FACSCalibur flow cytometer (BD Biosciences
Corp, San Jose, CA) [23]. Human MMP-1 in culture
supernatant was assayed by ELISA reagent (RayBiotech
Inc. Norcross, GA, USA).
Flow cytometry of adhesion molecules and gp130 on cell 
surface
Cells were resuspended in cold PBS and blocked with 2%
human pooled serum at room temperature for 15 min-
utes, followed by washing with PBS, cells were incubated
with the FITC-conjugated mouse anti-human ICAM-1 or
VCAM-1 monoclonal antibodies, or FITC-conjugated
mouse IgG1 isotypic control (BD Pharmingen) at 4°C in
dark for 45 minutes. For the detection of surface expres-
sion of gp130, unconjugated mouse-anti-human gp130 (R
& D Systems) followed by secondary FITC-conjugated
anti-mouse IgG antibodies (BD Pharmingen) were used
for the staining. After washing, cells were fixed with 1%
p a r a f o r m a l d e h y d e  i n  P B S .  E x p r e s s i o n  o f  c e l l  s u r f a c e
adhesion molecules and gp130 on 5,000 viable cells was
then quantitatively analyzed by flow cytometry (FACS-
Calibur flow cytometer, BD Biosciences) in terms of
mean fluorescence intensity (MFI).
Intracellular staining of activated (phosphorylated) 
signaling molecules
The intracellular expression of phosphorylated signaling
molecules was determined using previously established
intracellular staining assay [23]. Briefly, cells were fixed
with pre-warmed BD Cytofix Buffer (4% paraformalde-
hyde) for 10 minutes at 37°C after stimulation by IL-27.
After centrifugation, cells were permeabilized in ice-cold
methanol for 30 minutes and then stained with mouse
anti-human phosphorylated AKT, phosphorylated JAK2,
phosphorylated JNK, phosphorylated signal transducers
and activators of transcription (STAT)1(pY701) (BD
Pharmingen) and phosphorylated PI3K (Cell Signaling
Technology, Beverly, MA, USA) monoclonal antibodies
or mouse IgG1 isotypic control (BD Pharmingen) for 60
minutes followed by FITC conjugated goat anti-mouse
secondary antibody (BD Pharmingen) for another 45
minutes at 4°C in the dark. Cells were then washed, resus-
pended and subjected to analysis. Expression of intracel-
lular phosphorylated signaling molecules of 5,000 viableWong et al. Arthritis Research & Therapy 2010, 12:R129
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cells was analyzed by flow cytometry (FACSCalibur, BD
Biosciences) as MFI.
Statistical analysis
Plasma concentrations of IL-27 were expressed as median
(interquartile range, IQR) as they were not in Gaussian
distribution and its difference between RA and control
groups was assessed by Mann-Whitney rank-sum test.
The statistical significance of differences of other param-
eters was determined by one-way ANOVA. The values
were expressed as mean ± SD from three independent
experiments. Any difference with a P-value less than 0.05
was considered significant. When ANOVA indicated a
significant difference, the Bonferroni post hoc test was
then used to assess the difference between groups. All
analyses were performed using the Statistical Package for
the Social Sciences (SPSS) statistical software for Win-
dows, version 16.0 (SPSS Inc, Chicago, IL, USA).
Results
Plasma concentration of IL-27 in RA
The recruited RA patients (female:male = 97:15) cohort
was found to have mean age of 53 ± 9 (range 31 to 83
years) while control subjects (female:male = 40:6) have a
mean age of 47 ± 7 (range 25 to 62 years). Plasma concen-
tration of IL-27 was found to be significant higher in RA
patients than that in control subjects (11.7 (7.2 to 19.2) vs
7.1 (4.9 to 10.0) ng/ml, P < 0.001).
FLS express functional IL-27 receptor
In view of the elevated plasma concentration of IL-27 in
RA patients, we then assessed the expression of IL-27
receptors and the effect of IL-27 on FLS from RA and
control subjects. We first examined the gene expression
of IL-27 receptor complex, gp130 and WSX-1, of FLS
while PBMC were used as positive cell control. Quantita-
tive real time PCR analysis showed that gp130 and WSX-
1 mRNA was highly expressed in control and RA-FLS,
and PBMC (Figure 1A, B). Consistent with mRNA level,
flow cytometric analysis showed that gp130 constitutively
expressed on control and RA-FLS, and human CD4 + T
cells (positive control) (Figure 1C). Because of the lack of
commercial available anti-human WSX-1 antibody for
flow cytometry, we confirmed the protein expression of
WSX-1 of RA and control FLS using Western blot with
PBMC as positive cell control (Figure 1D).
IL-27 up-regulated ICAM-1 and VCAM-1 expression on the 
cell surface of FLS
Figure 2A, C show that IL-27 (50 ng/ml) could induce sig-
nificantly higher cell surface expression of ICAM-1 and
VCAM-1 on RA-FLS than control FLS at 48 h (all P <
0.01). In the kinetics and dose response of IL-27-inducing
effects on the surface expression of ICAM-1 and VCAM-
1, we found that IL-27 (10 to 100 ng/ml) could signifi-
cantly up-regulate the surface expression of ICAM-1 at
all the incubation times (12 h to 48 h) in a dose and time
dependent manner (Figure 2B, D). Furthermore, IL-27
induced significantly higher expressions of ICAM-1 and
VCAM-1 on RA-FLS than that of control FLS (Figure 2B,
D). In view of these results, we mainly used the optimal
incubation time (48 h) and dose (50 ng/ml) of IL-27 in the
following studies.
IL-27 could enhance CCL2, CXCL9, CXCL10 and MMP-1 
production from FLS
As shown in Figure 3, IL-27 could induce significantly
higher release of inflammatory chemokine CCL2, CXCL9
and CXCL10 from RA-FLS than that of control FLS (all P
< 0.05). In the kinetics and dose effect of IL-27-inducing
chemokine release, we found that IL-27 (10 to 100 ng/ml)
could significantly induce the release of chemokines at all
the incubation times (12 to 48 h) in a dose and time
dependent manner. IL-27 a induced significantly higher
amount of chemokines from RA-FLS than that of control
FLS (Figure 3).
Furthermore, IL-27 (50 ng/ml) could induce MMP-1
(13.8 ng/ml) release comparing with medium control (9.4
ng/ml) from RA-FLS but IL-27 (10 to 100 ng/ml) cannot
induce any MMP-1 release from control FLS.
Enhanced up-regulation of adhesion molecules and the 
release of chemokines upon combined treatment of IL-27 
and TNF-α or IL-1β
As pro-inflammatory cytokine TNF-α and IL-1β play
crucial inflammatory roles in the joints of patients [24],
we further investigate the combined effect of IL-27, TNF-
α and IL-1β on the activation of FLS. Figures 4 and 5
show that the combined treatment of IL-27 and TNF-α or
IL-1β resulted in additive or synergistic up-regulation of
ICAM-1 and VCAM-1 expression and the release of
CXCL9 and CXCL10 of RA-FLS (all P < 0.01). Moreover,
combined treatment of IL-27 and TNF-α could also
exhibit synergistic induction of CCL5 from RA-FLS, and
CXCL9 and CXCL10 from control FLS (both P < 0.05).
Effects of IL-27 on the activation of STAT1, JAK-2, AKT, PI3K 
and JNK signaling pathways in FLS
Using intracellular fluorescence staining by flow cytome-
t r y ,  w e  m e a s u r e d  t h e  M F I  o f  p h o s p h o r y l a t e d  S T A T 1 ,
JAK-2, AKT, PI3K, and JNK in permeabilized FLS upon
IL-27 stimulation. IL-27 could induce significant phos-
phorylation of STAT1, AKT, PI3K and JNK in both RA
and control FLS (Figure 6A, C, D, E), and JAK-2 in RA-
FLS (Figure 6B), all within five minutes. IL-27 could
induce significantly higher phosphorylation of STAT1 in
RA-FLS than that of control FLS (Figure 6A).Wong et al. Arthritis Research & Therapy 2010, 12:R129
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Figure 1 Expression of functional IL-27 heterodimeric receptor on FLS. (A, B). Total RNA was extracted from control FLS, RA-FLS and PBMC (pos-
itive control), followed by quantitiatve real time RT-PCR analysis for gp130, WSX-1 and GAPDH (house keeping gene) expression. (C) Representative 
histograms of cell surface expression of gp130 on control FLS, RA-FLS and human CD4+T cells (positive control) determined by flow cytometry. (D) 
Representative Western blot analysis of WSX-1 protein expression of control FLS, RA-FLS and PBMC (positive control). GAPDH was used as protein con-
trol to ensure an equal amount of loaded protein. All the experiments were performed in three independent replicates.
M, 100 base-pair molecular size marker; PBMC, peripheral blood mononuclear cells.
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Figure 2 Effect of IL-27 on the cell surface expression of adhesion molecules on control and RA-FLS. (A, C). Control and RA-FLS were cultured 
with IL-27 (50 ng/ml) for 48 h and then the surface expression of (A) ICAM-1 and (C) VCAM-1 was analysed by flow cytometry. The modulation of sur-
face expression of adhesion molecules are shown in bar chart as MFI. Results have been normalized by subtracting appropriate isotypic control and 
are expressed as the arithmetic mean plus SD of three independent experiments. Representative histograms of cell surface expression of (A) ICAM-1 
and (C) VCAM-1 on control FLS and RA-FLS were determined by flow cytometry. (B, D) Control and RA-FLS were stimulated with IL-27 (0 to 100 ng/
ml) for 12 to 48 h and then the surface expression of (B) ICAM-1 and (D) VCAM-1 was analysed by flow cytometry. Results have been normalized by 
subtracting appropriate isotypic control and are expressed as the arithmetic mean SD of MFI from triplicate experiments. CTL: control, **P < 0.01, ***P 
< 0.001.Wong et al. Arthritis Research & Therapy 2010, 12:R129
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Figure 3 Dose- and time-dependent effect of IL-27 on the induction of chemokine release from control and RA-FLS. Control and RA-FLS were 
cultured with IL-27 (50 ng/ml) for 48 h and induction of (A) CCL2, (C) CXCL9 and (E) CXCL10 was analysed by CBA using flow cytometry. (B, D, F) 
Control and RA-FLS were stimulated with IL-27 (0 to 100 ng/ml) for 12 to 48 h and inductions of (B) CCL2, (D) CXCL9 and (F) CXCL10 were analysed by 
CBA using flow cytometry. *P < 0.05, **P < 0.01, ***P < 0.001.
gWong et al. Arthritis Research & Therapy 2010, 12:R129
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Figure 4 The combined effects of IL-27 and TNF-α on the induction of adhesion molecules and chemokines. (A, B). Control and RA-FLS were 
cultured with or without IL-27 (50 ng/ml), and TNF-α (10 ng/ml) alone or in combination for 48 h. Cell surface expression of (A) ICAM-1 and (B) VCAM-
1 was determined by flow cytometry. (C, D, E) Control and RA-FLS were cultured with or without IL-27 (50 ng/ml), and TNF-α (10 ng/ml) alone or in 
combination for 48 h. Release of (C) CXCL9, (D) CXCL10 and (E) CCL5 was determined by CBA using flow cytometry. Results are expressed as the arith-
metic mean plus SD of three independent experiments. **P < 0.01, ***P < 0.001 when compared between treatment group and medium control. #P 
< 0.05, ##P < 0.01 when compared between combined treatment group and single treatment group.Wong et al. Arthritis Research & Therapy 2010, 12:R129
http://arthritis-research.com/content/12/4/R129
Page 9 of 15
Effects of signaling molecule inhibitors on the expression 
of adhesion molecules and release of chemokines from FLS 
activated by IL-27
The cytotoxicities of different signaling molecule inhibi-
tors on FLS were first determined by MTT assay. We
used the optimal concentrations of AG490 (10 μM),
LY294002 (10 μM), PD98059 (10 μM), SB203580 (20 μM),
and SP600125 (10 μM) with significant inhibitory effects
without any cell toxicity. As shown in Figure 7, PI3K
inhibitor LY294002 and JNK inhibitor SP600125 could
Figure 5 The combined effects of IL-27 and IL-1β on the induction of adhesion molecules and chemokines. (A, B). Control and RA-FLS were 
cultured with or without IL-27 (50 ng/ml), and IL-1 (20 ng/ml) alone or in combination for 48 h. Cell surface expression of (A) ICAM-1 and (B) VCAM-1 
was determined by flow cytometry. (C, D) Control and RA-FLS were cultured with or without IL-27 (50 ng/ml), and IL-1 (20 ng/ml) alone or in combi-
nation for 48 h. Release of (C) CXCL9 and (D) CXCL10 was determined by CBA using flow cytometry. Results are expressed as the arithmetic mean plus 
SD of three independent experiments. **P < 0.01, ***P < 0.001 when compared between treatment group and medium control. #P < 0.05, ##P < 0.01 
when compared between combined treatment group and single treatment group.
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Figure 6 Effects of IL-27 on intracellular STAT-1, JAK-2, AKT, JNK and PI-3K activities in FLS. Control or RA-FLS were incubated with IL-27 (50 
ng/ml) from 0 to 30 minutes. The amounts of intracellular phosphorylated signaling molecules in 5,000 permeabilized cells were measured by flow 
cytometry. Results of (A) phosphorylated STAT-1, (B) phosphorylated JAK-2, (C) phosphorylated AKT, (D) phosporylated PI3K and (E) phosphorylated 
JNK are shown in MFI subtracting corresponding isotypic control and are expressed as the arithmetic mean plus SD of three independent experi-
ments. Representative histograms illustrate the intracellular expression of (A) phosphorylated STAT-1, (B) phosphorylated JAK-2, (C) phoshorylated 
AKT, (D) phosphorylated PI3K and (E) phosphorylated JNK in control or RA-FLS. The isotypic control represents the cell populations stained with anti-
mouse IgG1 isotype control. *P < 0.05, **P < 0.01 and ***P < 0.001 when compared between groups denoted by horizontal lines.Wong et al. Arthritis Research & Therapy 2010, 12:R129
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Figure 7 Effects of signaling molecule inhibitors on IL-27-induced expression of adhesion molecule and chemokines of control and RA-FLS. 
Control and RA-FLS were pretreated with AG490 (AG, 10 μM), LY294002 (LY, 10 μM), SB203580 (SB, 20 μM), SP600125 (SP, 10 μM) or PD98059 (PD, 10 
μM) for one hour followed by incubation with or without IL-27 (50 ng/mL) in the presence of inhibitors for further 48 h. Surface expression of (A) ICAM-
1 and (B) VCAM-1 of 5,000 cells was assessed by flow cytometry as MFI. Release of (C) CXCL10, (D) CCL2 and (E) CXCL9 was determined by CBA using 
flow cytometry. Results are expressed as the arithmetic mean plus SD from three independent experiments. DMSO (0.1%) was used as the vehicle 
control. **P < 0.01, ***P < 0.001 when compared between groups denoted by horizontal lines.Wong et al. Arthritis Research & Therapy 2010, 12:R129
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significantly suppress IL-27-induced ICAM-1 expression
on the cell surface of control FLS, and IL-27-induced
ICAM-1 and VCAM-1 on RA-FLS (P < 0.05). Regarding
chemokine release, PI3K inhibitor LY294002 and JNK
inhibitor SP600125 could suppress IL-27 induced CCL2,
CXCL9 and CXCL10 from control FLS, JAK inhibitor
AG490, PI3K inhibitor LY294002 and JNK inhibitor
SP600125 could suppress IL-27 induced CCL2 and
CXCL10 release from RA-FLS, and JAK inhibitor AG490
and PI3K inhibitor LY294002 could inhibit IL-27 induced
CXCL9 release from RA-FLS (Figure 7).
Discussion
To investigate the immunopathological roles of inflam-
matory cytokine IL-27 on joint inflammation, we first
confirm the significantly elevated plasma level of IL-27 in
RA patients than normal controls. Apart from immune
effector cells, recent study showed that IL-27 can also
activate non-immune effector cells such as keratinocytes
[25]. Our present expression analysis of IL-27 receptor
complex has suggested that IL-27 could activate other
non-immune cell targets such as joint FLS. Human FLS
constitutively expressed functional IL-27 receptor com-
plex WSX-1 and gp130, and STAT1 was phosphorylated
upon IL-27 stimulation (Figures 1 and 6). The present
results are therefore in concordance with the expression
of gp130 and WSX-1 on synovial biospsies [26-28]. IL-27-
mediated activation effects have been shown to be mainly
through the regulation of STAT1 phosphorylation
[13,25,29]. For example, IL-27 could activate STAT1 to
induce IL-12Rβ2 expression in naive CD4+T cells for Th1
differentiation [13]. IL-27-induced STAT1 activation was
associated with proinflammatory effects in human
monocytes and keratinocytes [25,29]. To further explore
the difference of the activating effects of IL-27 on RA and
control FLS, we performed functional and underlying
mechanistic studies.
In the present study, we found that IL-27 was able to
induce significantly higher expression of ICAM-1 and
VCAM-1 and to augment TNF-α- and IL-1β-induced
ICAM-1 and VCAM-1 on RA-FLS than that of control
FLS (Figures 4 and 5), thus providing a novel immunop-
athological mechanism of IL-27 mediated joint inflam-
mation in RA. ICAM-1 and VCAM-1 are transmembrane
glycoprotein of the immunoglobulin supergene family
expressed on many cell types. ICAM-1 and VCAM-1 par-
ticipate in leukocyte-leukocyte, leukocyte-endothelium,
and leukocyte-epithelium interactions and transendothe-
lial migration [30]. Expression of VCAM-1 on synovial
fibroblasts is also a clinical hallmark of RA [31]. Expres-
sion of these adhesion molecules on FLS has been impli-
cated in the pathogenesis inflammation in RA by the
induction of the infiltration of leucocytes into local joint
[32]. Because of the pivotal role of ICAM-1 and VCAM-1
in inflammation, antisense oligonucleotides, monoclonal
antibodies or blockage compound against ICAM-1 and
VCAM-1 have been demonstrated with therapeutic ben-
eficial effects in inflammatory diseases [33]. Expression of
ICAM-1 and VCAM-1 on epithelial cells can be up-regu-
lated by cytokines such as TNF-α, IFN-γ or IL-1δ [34,35].
We herein provided evidence that IL-27 is a potent
inducer of ICAM-1 and VCAM-1, especially in combina-
tion with TNF-α or IL-1δ, on RA-FLS but not control
FLS, thereby elucidating the selective pathological roles
of IL-27 in RA.
A panel of inflammatory cytokines such as TNF-α, IL-
1, IL-6, IL-23, and IL-2 families are active in the joints of
the patients with RA by causing inflammation, articular
destruction, and the comorbidities [24]. We also found
that IL-27 could induce a significantly higher amount of
IL-6 from RA-FLS than control FLS (P < 0.05, data not
shown). To examine whether IL-27 also modulates the
expression of chemokines in FLS, we found that IL-27 can
induce significantly higher release of inflammatory
chemokines CCL2, CXCL9 and CXCL10 from RA-FLS
than control FLS. Combined treatment of IL-27 and
TNF-α or IL-1β also resulted in the synergistic produc-
tion of CCL5, CXCL9 and CXCL10 of RA-FLS (Figures 4
and 5). CCL2, CCL5, CXCL9 and CXCL10 are crucial
inflammatory chemokines for the chemoattraction of
Th1 cells and macrophages [36]. Those chemokines may
also stimulate FLS to release other cytokines and MMP
for the cartilage degradation and pannus formation [36].
In fact, we observed that IL-27 could induce the release of
MMP-1 from RA-FLS but not control FLS. MMP-1 has
been suggested to correlate with the invasive growth of
FLS in RA [3]. Furthermore, CCL2, CCL5, CXCL9 and
CXCL10 have been shown to be highly expressed in syn-
ovial fluid and synovial tissue [37-39]. Stimulation of RA-
FLS with CCL2 and CCL5 can enhance the production of
IL-6 and CXCL8 [40], while CCL2, CXCL10, CCL5 and
CXCL9 induce the gelatinase and collagenase activities in
the supernatants of cultured FLS [41]. CCL2 and CCL5
can stimulate MMP production by chondrocytes, inhibit
proteoglycan synthesis and enhance proteoglycan release
from the chondrocytes [42]. In addition, CCL5 can
induce the expression of inducible nitric oxide synthase,
IL-6 and MMP in chondrocytes [43]. FLS cells are a kind
of primary cell without cell proliferation and division.
The FLS cell numbers were constant during culture and
therefore the constant cell number did not have any effect
on the chemokines and MMP concentrations being mea-
sured in the cell culture supernatant.
Although IL-27 alone could not activate CCL5 release
from RA and control FLS, IL-27 exhibited synergistic
effect with TNF-α to induce CCL5 release in RA-FLS.
Actually, TNF-α can induce the expression of CCL5 in
cultured FLS [44]. Our results show that RA-FLS exhibitsWong et al. Arthritis Research & Therapy 2010, 12:R129
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a lower level of TNF-induced ICAM-1 and VCAM-1
expression as compared to control FLS. It may be due to
the lower cell surface expression of TNFRp55 (data not
shown), the crucial TNF receptor component for the
expression of adhesion molecule ICAM-1 and VCAM-1,
on RA-FLS compared with control FLS [45,46]. However,
our previous study showed that the synergistic activating
effects of IL-27 and TNF-α on bronchial epithelial cells
were partially due to the IL-27 up-regulated expression of
TNF-α receptor p55TNFR [47]. IL-27 stimulation could
also lead to the increased expression of TNF-α and IL-1β
in primary human monocytes [14,48]. The above may
account for the synergistic effect of IL-27, TNF-α and IL-
1β for chemokine release. Since FLS, monocytes and Th1
cells play important roles in the pathogenesis of RA, the
enhanced production of ICAM-1 and VCAM-1, and
chemokines for macrophages and Th1 cells of RA-FLS
induced by IL-27, TNF-α and IL-1β should contribute to
the development of inflammation.
IL-27 has been reported to activate the JAK/STAT sig-
naling pathway in T lymphocytes [49], but the signaling
pathways of IL-27 in FLS have not been reported. We
have previously reported the involvement of ERK, JNK,
JAK and p38 MAPK pathways in the expression of adhe-
sion molecules and release of cytokines and chemokines
from activated bronchial epithelial cells upon exposure to
diverse stimuli such as TNF-α, IL-4, IL-13 and IL-31
[50,51]. IL-27 stimulation could lead to receptor-medi-
ated tyrosine phosphorylation of the STAT family [52].
Our study showed that incubation with IL-27 resulted in
STAT1 tyrosine phosphorylation within five minutes and
maintained it for 30 minutes in both control and RA-FLS,
w i t h  a  m o r e  po t e n t  a c t i v a t i o n  i n  RA - F LS  ( F i g u r e  6 A ) .
This discrepancy may account for the higher induction of
adhesion molecules and release of chemokine upon IL-27
stimulation in RA-FLS. We also found that PI3K-AKT
and JNK pathways were activated in both RA and control
FLS in response to IL-27, whereas JAK-2 in RA-FLS was
activated upon IL-27 activation (Figure 6). Actually, pre-
vious studies have revealed that JNK and AKT involve the
inflammatory mechanisms of FLS in RA [53,54].
Using selective inhibitors that could suppress the acti-
vation of their corresponding signaling pathways, we fur-
ther elucidated the involvement of different signaling
pathways in regulating expression of adhesion molecules
and chemokines of FLS. These inhibition experiments
demonstrated that the IL-27-induced up-regulation of
ICAM-1 on control FLS, and ICAM and VCAM-1 on
RA-FLS was regulated by the activation of intracellular
PI3K-AKT and JNK pathways (Figure 7). Regarding the
chemokine release, IL-27 induced CXCL9 and CXCL10
from control FLS, CCL2 and CXCL10 from RA-FLS and
CXCL9 from RA-FLS was found to be mediated by PI3K
and JNK pathways, JAK, PI3K and JNK pathways, and
JAK and PI3K pathways, respectively (Figure 7). The
above discrepancy of the intracellular signaling mecha-
nisms between RA and control FLS for the induction of
adhesion molecules and chemokines indicates the dis-
tinct signaling pathways in inflammatory responses. Such
induction of chemokines by IL-27 in RA-FLS was not
completely inhibited by those inhibitors, other unidenti-
fied signaling pathways might therefore contribute to the
chemokine expression. Further experiments may be
required to investigate the regulatory mechanisms of dif-
ferent signaling molecules and transcription factors for
the induction of chemokines in human FLS upon
cytokine treatment.
Using a murine model, IL-27 can exhibit a suppressive
effect on inflammation and can attenuate collagen-
induced arthritis when administered at the onset of the
disease via the blocking of Th17 differentiation from
naïve T helper cells [17,55,56]. On the other hand, the late
onset of IL-27 was unable to downregulate Th17 in estab-
lished RA, thereby inducing the inflammation of the
ongoing adjuvant-induced arthritis in vivo [57]. In view of
that, our study using FLS derived from normal subjects
and established RA patients, therefore, only exhibits the
activating effects rather than the suppressive effects of IL-
27. Since IL-27 is detected at significant concentrations in
the joints of patients with ongoing RA, neutralization of
IL-27p28 has been suggested as a novel therapy [57]. Pre-
vious therapeutic approaches relied on disease-modifying
antirheumatic drugs (DMARDs) such as methotrexate
and sulfasalazine that had only partial clinical beneficial
effects and were associated with toxicity [24]. In view of
the application of antibodies for the blockade of TNF-
alpha, IL-1β and IL-6 receptor as treatments for RA,
other cytokines such as IL-27 may therefore offer alterna-
tive targets for therapeutic intervention or may be useful
as predictive biomarkers of established RA [57-59].
Because of the recent advances in the application of
MAPK and NF-κB inhibitors as potential anti-inflamma-
tory agents [60], our present study should also provide
new clues for the development of novel treatment for IL-
27-mediated RA inflammation.
Conclusions
Our results indicate the differential inflammatory IL-27-
mediated intracellular signaling mechanisms including
STAT1, PI3K-AKT, JNK and JAK pathways for the activa-
tion of RA and control FLS. They suggest the distinct sig-
naling pathways during inflammatory responses in RA.
As a result, IL-27 plays crucial immunopathological roles
in joint inflammation in RA by the induction of adhesion
molecules, cytokines and chemokines, especially com-
bined with TNF-α and IL-1β. Our study also provides a
biochemical basis for the development of a new modality
for RA.Wong et al. Arthritis Research & Therapy 2010, 12:R129
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